Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital

PADI4 Polymorphisms Confer Risk of Anti-CCP-Positive Rheumatoid Arthritis in Synergy With HLA-DRB1*04 and Smoking

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Soluble Urokinase Plasminogen Activator Receptor (suPAR) as a Biomarker of Systemic Chronic Inflammation

    Research output: Contribution to journalReviewResearchpeer-review

  2. Mitochondrial-Linked De Novo Pyrimidine Biosynthesis Dictates Human T-Cell Proliferation but Not Expression of Effector Molecules

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Applicability of Small-Molecule Inhibitors in the Study of Peptidyl Arginine Deiminase 2 (PAD2) and PAD4

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Prevalence and duration of anti-SARS-CoV-2 antibodies in healthcare workers

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Humoral response to two doses of BNT162b2 vaccination in people with HIV

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

Peptidylarginine deiminases (PADs) catalyze citrullination, a post-translational modification playing a pathogenic role in anti-citrullinated protein antibody (ACPA)-positive rheumatoid arthritis (RA). The interplay between single nucleotide polymorphisms (SNPs) in the PADI genes and known risk factors for ACPA-positive RA, including smoking, HLA-DR4 and -1, and the PTPN22 R620W polymorphism, was investigated. We typed four PADI2 SNPs, four PADI4 SNPs, and the PTPN22 R620W SNP in 445 Danish RA patients and 533 age-matched healthy controls, as well as in 200 North American RA patients and 100 age- and sex-matched controls. The HLA-DRB1 locus was typed in the Danish cohort. Logistic regression analyses, adjusted for age, sex, smoking status, and PTPN22 R620W, revealed increased risk of anti-CCP-positive RA in carriers of rs11203367(T) (OR: 1.22, p=0.03) and reduced risk in carriers of rs2240335(A) in PADI4 (OR: 0.82, p=0.04). rs74058715(T) in PADI4 conferred reduced risk of anti-CCP-negative RA (OR: 0.38, p=0.003). In HLA-DRB1*04-positive individuals, specifically, the risk of anti-CCP-positive RA was increased by carriage of PADI4 rs1748033(T) (OR: 1.54, p=0.007) and decreased by carriage of PADI4 rs74058715(T) (OR: 0.44, p=0.01), and we observed an interaction between these SNPs and HLA-DRB1*04 (p=0.004 and p=0.008, respectively) Thus, PADI4 polymorphisms associate with ACPA-positive RA, particularly in HLA-DRB1*04-positive individuals, and with ACPA-negative RA independently of HLA-DRB1*04.

Original languageEnglish
Article number707690
JournalFrontiers in Immunology
Pages (from-to)707690
Publication statusPublished - 2021

Bibliographical note

Copyright © 2021 Massarenti, Enevold, Damgaard, Ødum, Garred, Frisch, Shelef, Jacobsen and Nielsen.

    Research areas

  • Adult, Aged, Aged, 80 and over, Anti-Citrullinated Protein Antibodies/immunology, Arthritis, Rheumatoid/genetics, Denmark, Female, Genetic Predisposition to Disease, HLA-DRB1 Chains/genetics, Humans, Male, Middle Aged, Polymorphism, Single Nucleotide, Protein-Arginine Deiminase Type 4/genetics, Smoking/adverse effects

ID: 72502011